CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

about

Present Status and Future Challenges of New Therapeutic Targets in Preclinical Models of Stroke in Aged Animals with/without Comorbidities.

P2860

Q47712203-6C39510D-B504-41A7-AAA4-E6338B128C50

P2860

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

Item

http://www.wikidata.org/entity/Q47909228

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

@en

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

@nl

type

Item

label

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

@en

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

@nl

prefLabel

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

@en

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

@nl

P1476

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

@en

P2093

Alexandra C Chadwick

http://www.w3.org/2001/XMLSchema#string

Kiran Musunuru

http://www.w3.org/2001/XMLSchema#string

P2860

Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

RNA-guided human genome engineering via Cas9

Targeting DNA double-strand breaks with TAL effector nucleases

Multiplex genome engineering using CRISPR/Cas systems

Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease

Mutation in LDL receptor: Alu-Alu recombination deletes exons encoding transmembrane and cytoplasmic domains

RNA-programmed genome editing in human cells

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

In vivo genome editing restores haemostasis in a mouse model of haemophilia

P304

12-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/ATVBAHA.117.309326

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28838920

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

CRISPR

dyslipidemias

P932

5832026

http://www.w3.org/2001/XMLSchema#string

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

about

P2860

P2860

CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932